The FDA recently instituted the "breakthrough therapy designation" as a way to more quickly get drugs for serious, unmet medical needs to the market. Today, orphan drugmaker Alexion Pharmaceuticals (NASDAQ: ALXN ) was the latest biotech to announce that its experimental hypophosphatasia drug has been granted this designation. In the following video, health-care analyst Max Macaluso discusses the importance of this news for both patients and investors.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.